April 20, 2016

Future of Psychiatry – Professor Jeffrey Lieberman

Professor Lieberman was President of the American Psychiatric Association for DSM-5, the latest edition of the controversial diagnostic manual used in the US that caused a transatlantic row, he was involved in the early development of the antipsychotic drug Clozapine, led world-leading studies into treatments for schizophrenia and Alzheimer’s and worked on the US government’s Mental Health Parity and Addiction Equity Act, The Patient Protection and Affordable Care Act and the Helping Families in Mental Health Crisis Act.

This Expert Encounter came journalists a chance to discuss with Prof. Lieberman his views ranging from over-medicalisation to the science of psychiatry, DSM-5, or what governments need to do to really tackle mental health.

The Expert Encounter coincides with Prof. Lieberman being invited to the UK for a lecture about the future of psychiatry at the Royal College of Psychiatrists who are changing their core training so that the next generation of psychiatrists will have a greater understanding of neuroscience.

Speaker:

Prof. Jeffrey Lieberman, Lawrence C. Kolb Professor and Chairman, Department of Psychiatry, Columbia University College of Physicians and Surgeons. He is also Director of the New York State Psychiatric Institute and Psychiatrist-in-Chief of the New York Presbyterian Hospital-Columbia University Medical Center.